"Revive Therapeutics Phase 3 Trial For COVID Officially Enters The Regulatory Funnel"
On Sep 15, 2022 Share
On Wednesday, Revive Therapeutics Ltd. (CNSX: RVV) (OTCMKTS: RVVTF) took another step towards a resolution of its current Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine to treat COVID-19. The company announced that pursuant to its intention to pursue new primary symptoms endpoints, it has officially filed an amended protocol to the U.S. Food & Drug Administration.